Peru Class III/IV Registration Dossier: Ten Items, Sterilization Validation and Clinical Evaluation

Regulatory information verified as of October 29, 2026

1. Key takeaways

The Class III and Class IV dossier in Peru builds on the 8 items required for Class II by adding item 9, the sterilization process validation report, and item 10, the clinical evaluation report, while item 4, the technical report, must additionally provide a diagram of the basic manufacturing process, for a total of 10 items. What the three additions share is a common character: none of them is a descriptive document. They are all verification documents, and when reviewers read them, the question asked is whether the evidence is sufficient to support the conclusion, not whether the narrative is complete. This distinction drives how these files must be written, sequenced, and resourced. A Class III or IV project is dominated by these verification activities, which depend on a frozen design and process baseline and cannot be compressed at the end of the schedule without repeating work.

2. Legal basis

Regulatory information verified as of October 29, 2026.

3. Expert insights

Insight 1: The process flow diagram is the precondition for the existence of item 9 sterilization validation, not an illustration.

The function of the basic manufacturing process flow diagram is to mark the critical process steps and the critical control points. Without this diagram, the sterilization validation report has no identifiable validation object: the reviewer cannot determine before which process step sterilization occurs, which assembly steps remain after the sterile barrier is formed, and which steps introduce a possibility of recontamination. The two documents must therefore be written in a synchronized manner: the flow diagram comes first, the quality management points are anchored on it, and the validation report is mounted point by point against those anchors. Reducing the flow diagram to a simple block diagram running from parts in to product out cancels its function within the technical file entirely.

Insight 2: Item 9 demands validation of a process, not testing of a product.

The conformity of a sterile device cannot be demonstrated by sampling and testing the finished product, because the act of sampling destroys the sterile state itself. The correct object of validation is the process: installation qualification, operational qualification, and performance qualification, together with periodic audits of dose or cycle parameters, form a continuous chain of evidence of process control. The review focus falls on the basis for setting the sterilization dose or parameters, the confirmation of the worst-case load, and whether the routine release monitoring is consistent with what was validated. If these three elements diverge, the product stands under validation conditions but not under actual production conditions, which is precisely the gap reviewers are trained to find.

Insight 3: The item 10 clinical evaluation report and local clinical trials are two different procedures.

A clinical evaluation report, the CER, is a systematic appraisal of existing evidence, drawing on data from equivalent device comparison, the literature, and post-market experience, and may also incorporate the sponsor own clinical investigation. D.S. N° 021-2017-SA, published on 2017-06-30, by contrast regulates the conduct of clinical trials within Peru, involving approval of protocols and results by the INS and approval of the trial products by DIGEMID. Conflating the two misleads companies into investing in local trials that are not necessary, and equally into assuming that having run a local trial satisfies the CER when the evidence is otherwise insufficient. On high-classification projects, the evidence strategy of the CER is defined first, and only then is a decision taken on whether the local trial pathway is entered at all.

Insight 4: Three of the 10 items are verification documents, and this shapes the resource structure of high-classification projects.

Item 9, item 10, and the validation and qualification activities triggered by the process flow diagram typically occupy the major share of the timeline in Class III/IV projects. They also cannot be rushed in parallel at will: sterilization validation depends on a frozen process, and the CER depends on a frozen technical design.

4. Practical recommendations

1. Freeze the process and the bill of materials before launching item 9 sterilization validation, to avoid revalidation caused by version changes.
2. Make the process flow diagram mark the critical steps, the critical control points, and the position of the sterilization node.
3. Ensure the sterilization validation report covers the basis for parameter settings, worst-case load confirmation, and the correspondence with routine monitoring.
4. Define the CER evidence strategy first: the combination of equivalence data, literature, and own clinical data, and the plan for closing evidence gaps.
5. Evaluate whether a local clinical trial is required separately under D.S. N° 021-2017-SA, and do not merge that decision into the CER schedule.
6. Set the submission date backward from the 66 working days review clock, reserving ample time for external partners on the CER and sterilization validation.

5. Verification checklist

□ All 10 items are complete under Title IV

□ Item 4, the technical report, contains the basic manufacturing process flow diagram with the sterilization node marked

□ Item 9, the sterilization process validation report, covers installation, operational, and performance qualification plus periodic review

□ The consistency between worst-case load and routine release monitoring is explained

□ Item 10, the CER, states the data source combination and the treatment of evidence gaps

□ Whether the local clinical trial pathway under D.S. N° 021-2017-SA applies has been assessed

□ The schedule is logged against both the 66 working days review clock and the 90 calendar days assessment ceiling for Class III/IV

Regulatory information verified as of October 29, 2026.

*GRZAN Regulatory Team*

GRZAN provides medical device registration support in Peru for manufacturers, importers, and authorized representatives, covering Class III/IV dossier assembly, sterilization validation review, clinical evaluation, and deficiency response. For inquiries, contact info@grzanglobal.com.